ChemoMetec A/S: financial analysis
Ratios worked out from 3 fiscal years of ChemoMetec A/S's statements, compared with 32 companies in Scientific Technical Instruments.
ChemoMetec A/S scorecard#
Passes 5 of the 5 checks that could be worked out. Fiscal year 2025; market cap of Aug 1, 2026.
Valuationnot known
- –P/E below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
- –Price to book below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
- –Price to sales below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
- –Free cash flow yield above 5%The market cap dates from 2026-08-01, more than 60 days ago.
- –Earnings yield above the 10-year Treasury yieldThe market cap dates from 2026-08-01, more than 60 days ago.
- –The price assumes slower growth than the last three years'The market cap dates from 2026-08-01, more than 60 days ago.
Growth2 of 2
- ✓Revenue grew in the newest year1.2%Revenue up 1.2% in fiscal 2025.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✓Earnings per share grew in the newest year1719.51 vs 1516.63Diluted EPS 1719.51 in fiscal 2025 against 1516.63 the year before (report's currency).
- –Net income higher than five years earlierNet income of five years earlier is not on file.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability3 of 3
- ✓Profitable in the newest year$30 MNet income $30 M in fiscal 2025.
- –Profitable in each of the last five yearsFive years of net income are not on file.
- ✓Operating margin above its peers' median49.1%49.1% against Scientific Technical Instruments's median of 9.1% (26 companies).
- ✓Return on equity above 15%27.7%27.7% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial healthnot known
- –Short-term assets cover short-term liabilitiesCurrent assets and liabilities are not on file.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- –Cash from operations positive in each of the last three yearsThree years of operating cash flow are not on file.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returnsnot known
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- –Share count up no more than 2% in a yearShare counts of two years are not on file.
- –Dividends and buybacks above 3% of the market valueThe market cap dates from 2026-08-01, more than 60 days ago.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (esef), the medians of Scientific Technical Instruments, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Piotroski F-score
Nine yes/no tests of whether the company's finances improved in the year. One point each.
- Made a profityes
- Operations brought in cashyes
- Return on assets roseyes
- Cash from operations exceeds profityes
- Long-term debt fell against assetsnot on file
- Current ratio rosenot on file
- No new shares issuednot on file
- Gross margin roseyes
- Asset turnover roseyes
Where the return on equity comes from
The DuPont split: margin, times how hard the assets work, times how much of them is financed by others.
Profitability#
| Fiscal year | Trend | 2025 | 2024 | 2023 | Median of peers | Ahead of |
|---|---|---|---|---|---|---|
| Gross margin | 95.1% | 93.9% | — | 44.4% | 100% | |
| Operating margin | 49.1% | 47.7% | — | 9.1% | 100% | |
| Net margin | 39.5% | 35.3% | — | 8.7% | 100% | |
| Return on equity | 27.7% | 28.2% | — | 3.9% | 90% | |
| Return on assets | 23.0% | 20.0% | — | 1.7% | 100% |
Growth#
| Fiscal year | Trend | 2025 | 2024 | 2023 | Median of peers | Ahead of |
|---|---|---|---|---|---|---|
| Revenue growth | 1.2% | — | — | 4.0% | 26% | |
| Net income growth | 13.4% | — | — | 7.8% | 62% | |
| Earnings per share growth | 13.4% | — | — | 9.7% | 60% |
Financial strength#
| Fiscal year | Trend | 2025 | 2024 | 2023 | Median of peers | Ahead of |
|---|---|---|---|---|---|---|
| Equity share of assets | 84.3% | 82.0% | — | 59.1% | 97% |
Cash#
| Fiscal year | Trend | 2025 | 2024 | 2023 | Median of peers | Ahead of |
|---|---|---|---|---|---|---|
| Free cash flow | $27 M | $27 M | — | $6 M | 54% | |
| Free cash flow margin | 35.6% | 35.8% | — | 14.3% | 100% | |
| Cash conversion | 104.2% | 118.8% | — | 134.8% | 22% | |
| Capital spending share of revenue | 5.5% | 6.0% | — | 2.2% | — |
Efficiency#
| Fiscal year | Trend | 2025 | 2024 | 2023 | Median of peers | Ahead of |
|---|---|---|---|---|---|---|
| Asset turnover | 0.58× | 0.57× | — | 0.58× | 48% |
How each figure is worked out#
- Gross margin
- Gross profit as a share of revenue.
- Operating margin
- Operating income as a share of revenue.
- Net margin
- Net income as a share of revenue.
- Return on equity
- Net income as a share of shareholders' equity (the average of the start and the end of the year). Not given when equity is negative.
- Return on assets
- Net income as a share of total assets (average of the year).
- Revenue growth
- Revenue against the year before.
- Net income growth
- Net income against the year before. Only when both years were profitable.
- Earnings per share growth
- Diluted earnings per share against the year before. Only when both were positive.
- Equity share of assets
- Shareholders' equity as a share of total assets.
- Free cash flow
- Cash from operations less capital spending.
- Free cash flow margin
- Free cash flow as a share of revenue.
- Cash conversion
- Cash from operations as a share of net income. Only when the year was profitable.
- Capital spending share of revenue
- Capital spending as a share of revenue.
- Asset turnover
- Revenue divided by total assets (average of the year).
Source: ChemoMetec A/S's statements: annual reports in the European single electronic format. Arithmetic on reported figures, in US dollars; nothing is estimated. A figure is blank when a line it needs is not in the statements on file, and left out when the result cannot be right (a margin from next to no revenue). "Ahead of" is the share of the 32 companies in Scientific Technical Instruments that ChemoMetec A/S is better than on that figure, using each company's newest fiscal year; yields use today's market value. Medians for every industry · Back to ChemoMetec A/S